Comparative Persistency with Newer agents used to Treat Type 2 Diabetes (T2dm) In the united states- canagliflozin Versus Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors and Glucagon-Like Peptide-1 (Glp-1) agonists
Abstract
Authors
J. Diels C. Neslusan